Literature DB >> 28562278

Maternal Use of Opioids During Pregnancy and Congenital Malformations: A Systematic Review.

Jennifer N Lind1,2, Julia D Interrante3,4, Elizabeth C Ailes3, Suzanne M Gilboa3, Sara Khan3,5,6, Meghan T Frey3, April L Dawson3, Margaret A Honein3, Nicole F Dowling3, Hilda Razzaghi3,2, Andreea A Creanga7,8, Cheryl S Broussard3.   

Abstract

CONTEXT: Opioid use and abuse have increased dramatically in recent years, particularly among women.
OBJECTIVES: We conducted a systematic review to evaluate the association between prenatal opioid use and congenital malformations. DATA SOURCES: We searched Medline and Embase for studies published from 1946 to 2016 and reviewed reference lists to identify additional relevant studies. STUDY SELECTION: We included studies that were full-text journal articles and reported the results of original epidemiologic research on prenatal opioid exposure and congenital malformations. We assessed study eligibility in multiple phases using a standardized, duplicate review process. DATA EXTRACTION: Data on study characteristics, opioid exposure, timing of exposure during pregnancy, congenital malformations (collectively or as individual subtypes), length of follow-up, and main findings were extracted from eligible studies.
RESULTS: Of the 68 studies that met our inclusion criteria, 46 had an unexposed comparison group; of those, 30 performed statistical tests to measure associations between maternal opioid use during pregnancy and congenital malformations. Seventeen of these (10 of 12 case-control and 7 of 18 cohort studies) documented statistically significant positive associations. Among the case-control studies, associations with oral clefts and ventricular septal defects/atrial septal defects were the most frequently reported specific malformations. Among the cohort studies, clubfoot was the most frequently reported specific malformation. LIMITATIONS: Variabilities in study design, poor study quality, and weaknesses with outcome and exposure measurement.
CONCLUSIONS: Uncertainty remains regarding the teratogenicity of opioids; a careful assessment of risks and benefits is warranted when considering opioid treatment for women of reproductive age.
Copyright © 2017 by the American Academy of Pediatrics.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28562278      PMCID: PMC5561453          DOI: 10.1542/peds.2016-4131

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  91 in total

1.  Neonatal addiction: a two-year study. Part I. Clinical and developmental characteristics of infants of mothers on methadone maintenance.

Authors:  C M Ramer; A Lodge
Journal:  Addict Dis       Date:  1975

2.  Drug use in pregnancy and congenital heart disease in offspring.

Authors:  M B Bracken
Journal:  N Engl J Med       Date:  1986-04-24       Impact factor: 91.245

3.  Methadone maintenance in pregnancy: a reappraisal.

Authors:  H L Brown; K A Britton; D Mahaffey; E Brizendine; A K Hiett; M A Turnquest
Journal:  Am J Obstet Gynecol       Date:  1998-08       Impact factor: 8.661

4.  Maternal illness, including fever and medication use as risk factors for neural tube defects.

Authors:  G M Shaw; K Todoroff; E M Velie; E J Lammer
Journal:  Teratology       Date:  1998-01

5.  Infrequent neonatal opiate withdrawal following maternal methadone detoxification during pregnancy.

Authors:  U Maas; E Kattner; B Weingart-Jesse; A Schäfer; M Obladen
Journal:  J Perinat Med       Date:  1990       Impact factor: 1.901

6.  Follow-up of methadone-treated and untreated narcotic-dependent women and their infants: health, developmental, and social implications.

Authors:  G S Wilson; M M Desmond; R B Wait
Journal:  J Pediatr       Date:  1981-05       Impact factor: 4.406

7.  Prescription drug use among pregnant women in opioid Maintenance Treatment.

Authors:  Ingunn Olea Lund; Svetlana Skurtveit; Anders Engeland; Kari Furu; Edle Ravndal; Marte Handal
Journal:  Addiction       Date:  2012-10-18       Impact factor: 6.526

8.  The use of tricyclic antidepressants in methadone maintained pregnant women and infant outcome.

Authors:  L Green; S Ehrlich; L Finnegan
Journal:  NIDA Res Monogr       Date:  1988

9.  Vital signs: variation among States in prescribing of opioid pain relievers and benzodiazepines - United States, 2012.

Authors:  Leonard J Paulozzi; Karin A Mack; Jason M Hockenberry
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2014-07-04       Impact factor: 17.586

10.  Vital Signs: Demographic and Substance Use Trends Among Heroin Users - United States, 2002-2013.

Authors:  Christopher M Jones; Joseph Logan; R Matthew Gladden; Michele K Bohm
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2015-07-10       Impact factor: 17.586

View more
  30 in total

1.  Factors associated with treatment retention in pregnant women with opioid use disorders prescribed methadone or electing non-pharmacological treatment.

Authors:  Brandi Jancaitis; Sydney Kelpin; Saba Masho; James May; Nancy A Haug; Dace Svikis
Journal:  Women Health       Date:  2019-05-08

Review 2.  Maternity Care for Pregnant Women with Opioid Use Disorder: A Review.

Authors:  Abigail H Rizk; Sara E Simonsen; Leissa Roberts; Lisa Taylor-Swanson; Jennifer Berkowicz Lemoine; Marcela Smid
Journal:  J Midwifery Womens Health       Date:  2019-08-12       Impact factor: 2.388

3.  Surveillance for Emerging Threats to Pregnant Women and Infants.

Authors:  Meghan T Frey; Dana Meaney-Delman; Virginia Bowen; Mahsa M Yazdy; Sharon M Watkins; Phoebe G Thorpe; Margaret A Honein
Journal:  J Womens Health (Larchmt)       Date:  2019-08       Impact factor: 2.681

4.  Placental trophoblast transfer of opioids following exposures to individual or mixtures of opioids in vitro.

Authors:  Ninell P Mortensen; Maria M Caffaro; Rodney W Snyder; Yun L Yueh; Timothy R Fennell
Journal:  Exp Biol Med (Maywood)       Date:  2019-05-15

5.  Brief Report: Maternal Opioid Prescription from Preconception Through Pregnancy and the Odds of Autism Spectrum Disorder and Autism Features in Children.

Authors:  Eric Rubenstein; Jessica C Young; Lisa A Croen; Carolyn DiGuiseppi; Nicole F Dowling; Li-Ching Lee; Laura Schieve; Lisa D Wiggins; Julie Daniels
Journal:  J Autism Dev Disord       Date:  2019-01

6.  Subclinical and Overt Newborn Opioid Exposure: Prevalence and First-Year Healthcare Utilization.

Authors:  Zana Percy; Cole Brokamp; Jennifer M McAllister; Patrick Ryan; Scott L Wexelblatt; Eric S Hall
Journal:  J Pediatr       Date:  2020-05-15       Impact factor: 4.406

Review 7.  Management of the Cardiovascular Complications of Substance Use Disorders During Pregnancy.

Authors:  P Kaitlyn Edelson; Sarah N Bernstein
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-11-22

Review 8.  Public Health Surveillance of Prenatal Opioid Exposure in Mothers and Infants.

Authors:  Margaret A Honein; Coleen Boyle; Robert R Redfield
Journal:  Pediatrics       Date:  2019-01-17       Impact factor: 7.124

Review 9.  Opioid Use in Pregnancy.

Authors:  Amalia Londono Tobon; Erin Habecker; Ariadna Forray
Journal:  Curr Psychiatry Rep       Date:  2019-11-16       Impact factor: 5.285

10.  Opioid prescription claims among women aged 15-44 years-United States, 2013-2017.

Authors:  April D Summers; Elizabeth C Ailes; Michele K Bohm; Emmy L Tran; Cheryl S Broussard; Meghan T Frey; Suzanne M Gilboa; Jean Y Ko; Jennifer N Lind; Margaret A Honein
Journal:  J Opioid Manag       Date:  2021 Mar-Apr
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.